SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,180,209.38070502. The last known price of Ethereum is 2,270.17304981 USD and is up 0.59 over the last 24 hours. It is currently trading on 14230 active market(s) with $5,193,092,001.43 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

The reported multibillion-dollar Binance hack is driving concern about exchange security and possible selling pressure across crypto, alongside discussion of Ethereums weakness. Traders are divided between treating the selloff as a buying opportunity and expecting further downside as confidence and market sentiment remain strained.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 636,822,022.65079832 with 590,150,211.79771733 in circulation. The last known price of Solana is 94.05303263 USD and is down -1.56 over the last 24 hours. It is currently trading on 1189 active market(s) with $1,556,044,818.54 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solanas pullback amid broader crypto weakness dominates discussion, with traders also voicing concern that the reported Binance security incident could undermine confidence across the market. Some view the decline as a buying-and-staking opportunity, while others point to bearish momentum and warn of further downside.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is under pressure after weak Big Tech earnings and renewed doubts that heavy AI spending will generate sufficient returns, with traders debating whether the selloff marks a deeper tech correction or a temporary dip. Speculation about Iran talks and falling oil prices is also fueling hopes for a rebound, while others warn it could be a bear trap.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY discussion centers on a volatile rebound after a sharp selloff, with traders linking the move to falling oil and hopes for progress in U.S.-Iran talks, including a possible reopening of the Strait of Hormuz. Some see a relief rally, while others doubt the reports and warn that midterm uncertainty and concerns about AI-related tech valuations could keep markets choppy.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Escalating U.S.-Iran tensions and reported attacks threatening oil flows through the Strait of Hormuz are driving attention to USO and keeping crude prices elevated. Traders are divided between expecting further supply disruption and higher oil prices, and betting that diplomatic progress or a ceasefire could quickly unwind the geopolitical risk premium.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming quarterly report is the dominant focus, with traders debating whether strong AI-driven growth and guidance can meet expectations already viewed as exceptionally high. Bulls anticipate another beat, while skeptics point to the stocks rich valuation and recent AI-sector weakness as risks if guidance disappoints or merely meets the bar.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is drawing attention after a sharp semiconductor selloff, as investors question whether massive AI infrastructure spending will generate adequate returns; weak Intel guidance and broader tech selling added pressure. Traders are split between fears of an AI-trade unwind and expectations of a rebound, citing strong chip demand and oversold conditions.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a 52-week high ahead of expected Q3 earnings has fueled attention, with traders weighing BRIUMVIs growth and upcoming subcutaneous data against speculation about a buyout and short covering. No acquisition is confirmed, and some traders argue the rally may simply reflect earnings positioning and momentum.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its upcoming earnings report has traders focused on whether the ad-tech business can sustain growth amid concerns about the broader ad market, competition and analyst downgrades. Bulls argue the decline overlooks strong profitability and growth, while bears fear weaker results or guidance could deepen the downturn.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of a competing treatment for recurrent respiratory papillomatosis has focused attention on the threat to Precigens PAPZIMEOS and contributed to a sharp after-hours selloff. Traders disagree on how much competition it poses: some see Inovios surgery-free regimen as an advantage, while others point to Precigens first-mover position, established sales, and full approval.

statis crypto Watchlist

Bitcoin

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of +48.61% and +5.99%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?

Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics to Report Third Quarter 2026 Financial Results

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general...

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI (sparsentan) may modify the underlying disease pathophysiology in people with IgA nephropathy (IgAN). Data were shared today in an oral presentation at the...

AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy

AZN wins accelerated FDA approval for Ultomiris in IgA nephropathy, marking the fifth approved indication for the drug in the United States.

Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to Decline

Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 178,580 shares of its common stock to 33 new employees, consisting of inducement stock options to...

Travere to Present New Data Supporting FILSPARI (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO, October 21-25. The presentations highlight compelling new data on FILSPARI...

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law FirmPR NewswireNEW YORK, Sept. 30, 2026NEW YORK, Sept. 30, 2026/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI (sparsentan) in Focal Segmental Glomerulosclerosis

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders, directed to certain...

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>H.C. Wainwright analysts said the early data and the drug’s overall profile are “pointing in the right direction.”</li><li>Civorebrutinib has the potential to become “a best-in-class” treatment in its category, it added.</li><li>Travere will pay Everest Medicines $112.5 million upfront.</li></ul>Shares of Travere Therapeutics (TVTX) fell as much as 6% on Tuesday but recovered some of the losses after H.C. Wainwright raised its price target on the stock to $67 from $57 and kept a ‘Buy’ rating, an upgrade that followed the company’s announcement expanding its lineup of rare-kidney-disease treatments by licensing a promising new drug. &nbsp;The fresh price target implies a potential upside of about 49% from the stock’s last close.<h2 class="st-heading-2">TVTX’s Licensing Deal</h2>The licensing deal, announced Tuesday with China’s Everest Medicines, gives Travere exclusive rights to develop and sell the drug civorebrutinib in the United States and all other markets outside China and certain countries in East and Southeast Asia. Civorebrutinib is an oral pill still in early testing that is designed to calm overactive parts of the immune system that can damage the kidneys in rare diseases. These conditions include primary membranous nephropathy, focal segmental glomerulosclerosis, and minimal change disease—illnesses that currently have limited treatment options and leave many patients with few good choices.Early results from a small clinical study in patients with one of these kidney conditions were encouraging. The drug quickly lowered harmful antibodies and excess protein in the urine, helped more patients reach remission, and kept kidney function stable for up to a year, with few side effects reported so far. H.C. Wainwright analysts said the early data and the drug’s overall profile are “pointing in the right direction” and that civorebrutinib has the potential to become “a best-in-class” treatment in its category.Travere will pay Everest Medicines $112.5 million upfront. If the drug succeeds in later testing and reaches the market, Travere could pay up to about $1.03 billion in additional milestone payments, plus ongoing royalties on sales ranging from the high single digits to low double digits.Travere plans to study civorebrutinib next in patients with primary membranous nephropathy and certain forms of focal segmental glomerulosclerosis and minimal change disease, with the possibility of testing it in other related conditions later. The agreement is still subject to standard regulatory approvals, including antitrust clearance.How Did Retail Traders React?On Stocktwits, retail sentiment around TVTX stayed within the ‘bullish’ territory while message volume remained at ‘high’ levels.A Stocktwits user said that they are skeptical of the licensing deal until they see more data.<stembedurl>https://www.stocktwits.com/JFais/message/655087843</stembedurl>Another cheered the deal as “big news.”<stembedurl>https://www.stocktwits.com/buckyebullrider01/message/655078299</stembedurl><a href="https://stocktwits.com/symbol/TVTX">TVTX stock</a> has gained about 177% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-advances-110-billion-warner-bros-deal-reportedly-seeks-eu-approval/cZ0030AReDd">Paramount Skydance Advances $110B Warner Bros. Deal, Reportedly Seeks EU Approval</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Travere Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The licensing deal, announced Tuesday with China’s Everest Medicines, gives Travere exclusive rights to develop and sell the drug civorebrutinib in the United States.

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$TVTX Any  predictions for  tmrw’s  print?  Can  revs  exceed  $200M?  Can  PSFs  exceed  2,000  again?  Will  they  curtail  the  SG&A  and  R&D  spend?

Kelly Sheppard

$TVTX Advice  to  new  CEO:  SG&A  and  R&D  costs  are  simply too high.  Pare  down  the  R&D  agenda  substantially,  shrink  the  back  office functions,  and invest  in  more sales  &  support  teams.  Producing  $700  million  in  revenue,  should  yield  a  very  profitable  print—instead,  it’s all  being  consumed  in  the currently bloated organization and agenda.  Streamline,  singular focus,  dramatically scale  Filspari, and have  the  Board  announce  ‘exploring  strategic  alternatives’. A  bidding  war  would get  valuation  close  to  $100  /  share. $NVS has a 3.3% div  yield, if acquired in  shares, ride it  out  for  years. Let’s get  this done.

$TVTX — Q3 results on 2 Nov after the close. 
 
Information only — not investment advice. 
 
More details in our hub.

Merlintrader Trading Pub

📅 CATALYST REMINDER | $TVTX 
October 22–24, 2026 — Clinical Data Presentations 
Sparsentan analyses from SPARTAN, DUPLEX and PROTECT are part of the ASN Kidney Week program. Individual presentation times vary. 
More details in our hub. 
#TVTX #Biotech #KidneyWeek

Feed

News

Sentiment

Earnings

Fundamentals

Info

TVTX Travere Therapeutics Inc

Fundamentals

Latest TVTX News